Biocartis SA (Biocartis) is a molecular diagnostics company that provides personalized medicine for patients through its molecular diagnostics. The company undertakes the development of diagnostics technology platforms for multiplexed detection of bio-analytes, with oncology as its key focus area. Its Idylla is a molecular diagnostics system that provides easy access to clinical molecular diagnostic information. Biocartis also offers a wide range of oncology assays such as Idylla BRAF Mutation Test, Idylla KRAS Mutation Test, Idylla EGFR Mutation Test and Idylla NRAS Mutation. The company has partnership with Johnson & Johnson, and Abbot to develop diagnostics tests in other disease areas. It also has operations in Belgium. Biocartis is headquartered in Lausanne, Switzerland.
Biocartis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
2020 will be remembered for the COVID-19 pandemic, masks, social distancing protocol, alternate care sites, Moderna, Pfizer, BioNTech, AstraZeneca, RT-PCR, and serology testing (or all the above). However, in the midst of our response to the global pandemic, remarkable advancements were made in another great frontier in medicine that remains...
The global AI in medical diagnostics market is projected to reach USD 3,868 million by 2025 from USD 505 million in 2020, at a CAGR of 50.2% during the forecast period. Growth in this market is primarily driven by government initiatives to increase the adoption of AI-based technologies, increasing demand for AI tools in the medical field,...
The nucleic acid amplification, detection, and diagnostics market was valued at US$ 14,014.59 million in 2019 and is projected to reach US$ 38,162.68 million by 2027; it is expected to grow at a CAGR of 13.4% during 2020–2027. The growth of the nucleic acid amplification, detection, and diagnostics market is mainly attributed to the factors...
KEY FINDINGS The North America precision medicine market is projected to evolve with a CAGR of 9.67%, over the forecast years of 2021 to 2028. The region’s key market growth drivers include the rising focus of well-established diagnostics manufacturers to expand their portfolio in NGS-based molecular diagnostics, as well...
The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period. In the past decade, the demand for various health diagnostic tests has increased significantly across the globe. Currently, the market is mainly driven by growing awareness about...
The major factors responsible for the growth of the mammography market include the growing prevalence of breast cancer, technological advancements in the field of breast imaging, and investment from various organizations in breast cancer screening campaigns. - According to the Centers for Disease Control and Prevention (CDC) reports,...
275 pages •
By Global Industry Analysts
• Apr 2021
- Global Hepatitis Test Solution/Diagnosis Market to Reach $3.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Hepatitis Test Solution/Diagnosis estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.9 Billion by 2027, growing at a CAGR of 4.7% over...
The global irritable bowel syndrome (IBS) diagnostics market is expected to reach US$ 3,880.91 million by 2028 from US$ 2,470.61 million in 2020; it is estimated to grow at a CAGR of 5.9% from 2020 to 2028. Increasing prevalence of irritable bowel syndrome and associated conditions and increasing number of FDA approvals and diagnostics...
The global SIBO diagnostics market is expected to reach US$ 194,604.51 thousand by 2028 from US$ 138,324.23 thousand in 2020. It is estimated to grow at a CAGR of 4.4% from 2021 to 2028. Initially, jejunal aspiration and duodenal fluid analyses were used to diagnose SIBO.Due to the invasiveness of jejunal aspirates’ and duodenal fluids...
Summary Mobidiag Ltd (Mobidiag) operates as a biotechnology company that develops and markets products for molecular diagnosis of infectious diseases and test kits.The company’s products portfolio includes Novodiag, Amplidiag, and Prove-it. Its Amplidiag is a diagnostic test for high-volume screening of gastrointestinal...
Medical Devices Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.